Rivaroxaban versus enoxaparin after total knee arthroplasty

the control group should have been treated with at least 80 mg enoxaparin instead of only 60 mg per day. The enoxaparin dose should have been adjusted so as to obtain only 10–20% of normal extrinsic thrombin generation.

To achieve good haemostasis, some patients, especially patients with such a prothrombotic condition as total knee arthroplasty, can require much more enoxaparin than 60 mg/day. If these undertreated patients had been identified and treated with an adequate dose, enoxaparin—as the more physiological anticoagulant—would probably have been superior to rivaroxaban.